All

Phase 3 Data Published for Once-Nightly OSA Drug Candidate AD109

Results from the SynAIRgy trial show the investigational oral therapy AD109 significantly reduced airway obstruction and improved oxygenation in patients with obstructive sleep apnea.

All

Apnimed Acquires Global Rights to Additional Sleep Apnea Drug Candidate

Apnimed has acquired global rights to develop and commercialize a carbonic anhydrase inhibitor with promising phase 2 results for OSA.

All

Sleep Apnea Drug Candidate Significantly Improves Symptoms in Phase 2b Trial

Apnimed unveiled the full results of its MARIPOSA phase 2b trial of AD109, an investigational oral drug for obstructive sleep apnea.

First Patient Dosed in Second Phase 3 Trial of Oral Treatment for OSA

Dec 26, 2023 | Pharmaceuticals

SynAIRgy compares AD109 to placebo over six months in people with OSA who are intolerant of or refuse positive airway pressure therapy.

Rising Health Challenges Fuel Japan’s Sleep Apnea Market, Data Firm Finds

Nov 30, 2023 | Regional

Due to rising cases of stress, depression, obesity, extended work hours, and a high rate of diabetes, Japan’s market for sleep apnea diagnostic equipment is anticipated to see significant growth, according to a recent forecast.

Joint Venture Seeks to Develop Oral Therapies for Sleep Apnea

Nov 1, 2023 | Obstructive Sleep Apnea, Pharmaceuticals

The $150 million transaction supports early and clinical-stage pipeline development in OSA and related sleep disorders to find oral pharmacologic solutions for people who cannot use or tolerate current therapies.

Apnimed to Showcase Latest Findings on Investigational OSA Drug

Oct 19, 2023 | Emerging Compounds, Obstructive Sleep Apnea

Apnimed will showcase recent findings on its investigational oral obstructive sleep apnea drug, AD109, at World Sleep 2023.

First Patient Dosed in Phase 3 Trial of OSA Drug Candidate AD109

Sep 21, 2023 | Emerging Compounds, Obstructive Sleep Apnea

The first patient has been dosed in Apnimed’s phase 3 study of AD109, a drug candidate for obstructive sleep apnea.

Apnimed to Share New Data on AD109 and AD113 for OSA

Sep 6, 2023 | Emerging Compounds, Obstructive Sleep Apnea

Apnimed will present new research on drug candidates AD109 and AD113, targeting obstructive sleep apnea, at the European Respiratory Society’s International Congress 2023.

Apnimed Presents Positive Results of Sleep Apnea Drug Candidate

May 22, 2023 | Emerging Compounds, Obstructive Sleep Apnea

Based on consultation with the US Food and Drug Administration, Apnimed plans to begin two phase 3 registration trials in the second half of 2023.

Apnimed to Present Data on Investigational Oral Treatment for Sleep Apnea

May 16, 2023 | Emerging Compounds, Obstructive Sleep Apnea

Data from the phase 2b trial of Apnimed’s leading drug candidate for OSA will be featured at The American Thoracic Society’s ATS 2023 International Conference in Washington, DC.

Apnimed Secures Funding for Phase 3 Trials of Sleep Apnea Drug Candidate AD109

Jan 5, 2023 | Emerging Compounds, Obstructive Sleep Apnea

Enrollment for the clinical trials is expected to begin in the second quarter of 2023, pending discussions with the FDA.

Proof-of-Concept Crossover Study of Two Sleep Apnea Pill Candidates Shows Promising Results

Feb 3, 2022 | Emerging Compounds, Obstructive Sleep Apnea

Topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, crossover study of sleep apnea pill candidates.

Study Looks at Oral Pharmacologic OSA Treatments

Dec 17, 2021 | Obstructive Sleep Apnea

Apnimed announced the dosing of the first patient in a study of the company’s lead investigational oral medication for the treatment of OSA.

Sleep Specialist Becomes SVP, Medical Affairs at Sleep Apnea Pill Development Company Apnimed

Jul 27, 2021 | Emerging Compounds, Obstructive Sleep Apnea

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, has named David P. White, MD, senior vice president of medical affairs. In this role, White will...